A “Depolarization‐Activation” Strategy Targeting Microglia: Cuproptosis‐Mediated Immune Re‐Sensitization Nanoplatform in Glioma Therapy
- 4 March 2026
- journal article
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (41)
Abstract
Despite the necessity of repolarizing tumor‐associated microglia/macrophages (TAMs) to reverse the highly immunosuppressive microenvironment in gliomas, clinical translation is hindered by tumor heterogeneity and therapeutic dose safety concerns. Here, we develop a “depolarization‐activation” strategy: cuproptosis depolarizes TAMs to an “erased” stage regardless of tumor subtypes, leading to a universally enhanced susceptibility to immunoactivating agents. The cuproptosis inducer Elesclomol‐Cu (EsCu) and activation agent MK8931 are encapsulated into one nanoplatform with glioma targeting polymers (EsCu/MK@M‐P). Sub‐lethal level cuproptosis treatment significantly downregulates all polarization markers in TAMs, depolarizing TAMs to an immature state. MK8931 at a low dosage subsequently activates TAMs toward a tumor‐killing phenotype, achieving immunotherapeutic efficacy on glioma cells. In vitro and in vivo models, multi‐omics analysis, and patient‐derived organoids validate broad‐spectrum anti‐glioma potency and improved biosafety. Therefore, the “depolarization‐activation” strategy reveals that sub‐lethal hits erase the immunosuppressive property of tumor microenvironment for following immunoactivation, promisingly innovating current cancer immunotherapy strategies.Keywords
Funding Information
- National Natural Science Foundation of China (22378126)
- National Natural Science Foundation of China (22225805)
- National Key Research and Development Program of China (2021YFE0100400)
This publication has 38 references indexed in Scilit:
- Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progressionCancer Cell, 2026
- Multi-omic landscape of human gliomas from diagnosis to treatment and recurrenceCancer Cell, 2025
- Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalizationCancer Cell, 2024
- Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor ImmunotherapyAdvanced Science, 2024
- Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer ImmunotherapyAdvanced Materials, 2023
- Immunogenic Cell Death Inducing Metal Complexes for Cancer TherapyAngewandte Chemie International Edition, 2023
- Immunogenic cell death-inducing metal complexes: From the benchtop to the clinicCurrent Opinion in Chemical Biology, 2023
- Immunotherapy for glioma: Current management and future applicationCancer Letters, 2020
- Application of flash nanoprecipitation to fabricate poorly water-soluble drug nanoparticlesActa Pharmaceutica Sinica B, 2019
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010